SRC and renal cell carcinoma: From this screen, the PI3K/mTOR inhibitors NVP-BGT226 and Torin 2, the proteasome inhibitors Carfilzomib and Bortezomib, and the Src inhibitors Dasatinib and Saracatinib were selected for validation by 2D viability assays in all 5 TFE3-fusion RCC cell lines (Fig. 2B,C).